Literature DB >> 14508742

Prosthodontic treatment with implant fixed prosthesis for a patient with ectodermal dysplasia: a clinical report.

Behnoush Rashedi1.   

Abstract

Oral characteristics of ectodermal dysplasia (ED) include hypodontia or anodontia of the primary or permanent teeth, impacted teeth, malformed and widely spaced peg-like teeth, and underdeveloped alveolar ridges. Patients with this disease often need a multidisciplinary approach to treatment planning and dental treatment to regain appropriate function, esthetics, and comfort. The definitive treatment plan may include removable, fixed, or implant-supported prostheses or a combination of these options. Depending on the remaining available alveolar bone and the pattern of missing teeth, the ideal treatment option for an adult ED patient often includes the use of implants. This clinical report describes the multidisciplinary approach to diagnosis and treatment of ED in a 37-year-old woman. The treatment included a mandibular implant-supported fixed denture and a maxillary conventional overdenture fabricated to establish acceptable occlusal vertical dimension, esthetics, and oral function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508742     DOI: 10.1016/S1059-941X(03)00042-1

Source DB:  PubMed          Journal:  J Prosthodont        ISSN: 1059-941X            Impact factor:   2.752


  3 in total

Review 1.  Dental implant systems.

Authors:  Yoshiki Oshida; Elif B Tuna; Oya Aktören; Koray Gençay
Journal:  Int J Mol Sci       Date:  2010-04-12       Impact factor: 5.923

2.  Full mouth rehabilitation of an ectodermal dysplasia patient with implant-supported prostheses: a clinical report.

Authors:  Rahab Ghoveizi; Hakimeh Siadat; Sakineh Nikzad; Ghasem Ommati Shabestari; Yadolah Soleimani Shayesteh
Journal:  J Dent (Tehran)       Date:  2013-05

3.  Oral rehabilitation of a patient with ectodermal dysplasia with prosthodontics treatment.

Authors:  Srinivas Nallanchakrava
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.